Agenus Stock Rises Ahead of Investor Day Presentation [The Motley Fool]
Agenus Inc. (AGEN)
Last agenus inc. earnings: 3/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
agenusbio.com/investors
Company Research
Source: The Motley Fool
Maxx Chatsko (TMFBlackn) Author Bio Maxx has been a contributor to Fool.com since 0. He graduated from the State University of New York College of Environmental Science and Forestry (0) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (0) with a Master of Science in Materials Science & Engineering. What happened Shares of Agenus NASDAQ:AGEN The development-stage biopharmaceutical company is set to present clinical data from two drug candidates at the investor day: a combination therapy comprising AGEN0 and AGEN88, and AGEN8 as a monotherapy. All three experimental therapies are monoclonal antibodies being developed as oncology assets. As of :0 p.m. EST, the pharma stock Image source: Getty Images. So what In late December, Agenus initiated a phase / clinical trial of its therapy combining the company's two lead drug candidates: AGEN0 (balstilimab) and AGEN88 (zalifrelimab). The former inhibits CTLA-, while the latter inhibits PD-. Both proteins
Show less
Read more
Impact Snapshot
Event Time:
AGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGEN alerts
High impacting Agenus Inc. news events
Weekly update
A roundup of the hottest topics
AGEN
News
- Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers [Yahoo! Finance]Yahoo! Finance
- Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric CancersBusiness Wire
- Vaccine Adjuvants Market to Hit USD 0.96 Billion by 2029 with 6.5% CAGR | MarketsandMarkets™ [Yahoo! Finance]Yahoo! Finance
- Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus [Yahoo! Finance]Yahoo! Finance
- Agenus Inc. (NASDAQ: AGEN) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
AGEN
Earnings
- 11/12/24 - Miss
AGEN
Sec Filings
- 12/16/24 - Form 4
- 12/5/24 - Form 8-K
- 12/3/24 - Form 4
- AGEN's page on the SEC website